Zymeworks
ZYME
74 hedge funds and large institutions have $487M invested in Zymeworks in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 17 closing their positions.
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
13% more capital invested
Capital invested by funds: $431M → $487M (+$55.7M)
10% more funds holding
Funds holding: 67 → 74 (+7)
0.18% more ownership
Funds ownership: 50.07% → 50.26% (+0.18%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less call options, than puts
Call options by funds: $892K | Put options by funds: $1.27M
Top Buyers
Top Sellers
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$32M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$27.6M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$6.05M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.34M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.14M |
ZYME Hedge Fund Activity: Q3 2019 in Review
74 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Zymeworks (ZYME) for Q3 2019, worth a combined $487M — up 13% from $431M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ZYME positions and 17 closed out — a net gain of 7 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was Great Point Partners, adding an estimated $35.1M. The largest seller was Vivo Capital, exiting entirely with an estimated $32M sold.
- 74 institutional investors held Zymeworks (ZYME) as of Q3 2019, up from 67 in Q2 2019.
- Funds reported $487M of Zymeworks stock for Q3 2019, up 13% quarter-over-quarter.
- 24 funds opened new Zymeworks positions in Q3 2019 and 17 closed out, a net change of +7 holders.
- The largest Zymeworks buyer in Q3 2019 was Great Point Partners, an estimated $35.1M added.
- The largest Zymeworks seller in Q3 2019 was Vivo Capital, an estimated $32M sold.
Based on aggregated 13F filings for Q3 2019.